Calcitonin Gene-Related Peptide and Size of the Atrial Septal Defect in New-Onset Migraine After Transcatheter Closure: Results of a Preliminary Study

2012 ◽  
Vol 52 (6) ◽  
pp. 985-992 ◽  
Author(s):  
Shu-Hao Wei ◽  
Pi-Chuan Fan ◽  
Ping-Hung Kuo ◽  
Lih-Chu Chiou ◽  
Jou-Kou Wang
Keyword(s):  
Atrial Septal Defect ◽  
Septal Defect ◽  
Transcatheter Closure ◽  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Calcitonin Gene ◽  
Preliminary Study ◽  
New Onset

scholarly journals Diagnostic Accuracy of Serum Calcitonin Gene-Related Peptide and Apolipoprotein E in Migraine: A Preliminary Study

2021 ◽  
Vol Volume 14 ◽  
pp. 851-856
Author(s):  
Rabia Latif ◽  
Nazish Rafique ◽  
Lubna Al Asoom ◽  
Ahmed A Alsunni ◽  
Ayad Mohammed Salem ◽  
...  
Keyword(s):  
Diagnostic Accuracy ◽  
Apolipoprotein E ◽  
Calcitonin Gene Related Peptide ◽  
Serum Calcitonin ◽  
Related Peptide ◽  
Calcitonin Gene ◽  
Preliminary Study

Atrial fibrillation following transcatheter atrial septal defect closure: a systematic review and meta-analysis

Heart ◽  
2021 ◽  
pp. heartjnl-2021-319794
Author(s):  
Jonah Daniel Himelfarb ◽  
Healey Shulman ◽  
Christopher James Olesovsky ◽  
Rawan K Rumman ◽  
Laura Oliva ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Systematic Review ◽  
Atrial Septal Defect ◽  
Septal Defect ◽  
De Novo ◽  
Transcatheter Closure ◽  
Meta Analysis ◽  
Congenital Cardiac Anomalies ◽  
New Onset

ObjectiveThe ostium secundum atrial septal defect (ASD) is among the most common congenital cardiac anomalies diagnosed in adulthood. A known complication of transcatheter ASD closure is the development of new-onset atrial fibrillation and flutter (AFi/AFl). These arrhythmias confer an increased risk of postoperative stroke, thrombus formation and systemic emboli. This systematic review examines the burden of de novo AFi/AFl in adults following transcatheter closure and seeks to identify risk factors for AFi/AFl development.MethodsStudies were identified by a search of MEDLINE, EMBASE and Cochrane databases from inception until 29 April 2020. A meta-analysis of AFi/AFl incidence was performed using a random-effects model.ResultsA total of 31 studies met inclusion criteria, comprising 4788 adult patients without a history of AFi/AFl. Twenty-three studies were included in quantitative synthesis and demonstrated an overall incidence rate of 1.82 patients per 100 person-years of follow-up (I2=83%). In studies that enrolled only patients ≥60 years old, the incidence was 5.21 patients per 100 person-years (I2=0%). Studies with follow-up duration ≤2 years reported an incidence of 4.05 per 100 person-years (I2=55%) compared with a rate of 1.19 per 100 person-years (I2=85%) for studies with follow-up duration >2 years.ConclusionsThe incidence of new-onset AFi/AFl is relatively low following transcatheter closure of secundum ASDs. The rate of de novo AFi/AFl, however, was significantly higher in elderly patients. Shorter follow-up time was associated with a higher reported incidence of AFi/AFl.

scholarly journals New-onset migraine with aura after transcatheter closure of atrial septal defect

2012 ◽  
Vol 13 (6) ◽  
pp. 493-495 ◽  
Author(s):  
Yuji Kato ◽  
Daisuke Furuya ◽  
Hirotaka Ishido ◽  
Toshiki Kobayashi ◽  
Norio Tanahashi
Keyword(s):  
Atrial Septal Defect ◽  
Migraine With Aura ◽  
Septal Defect ◽  
Transcatheter Closure ◽  
New Onset

scholarly journals Preliminary study on androgen dependence of calcitonin gene-related peptide in rat penis

2005 ◽  
Vol 7 (1) ◽  
pp. 55-59 ◽  
Author(s):  
Zhou-Jun Shen ◽  
Shan-Wen Chen ◽  
Ying-Li Lu ◽  
Liao-Yuan Li ◽  
Xie-Lai Zhou ◽  
...  
Keyword(s):  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Calcitonin Gene ◽  
Preliminary Study

Monoklonale Antikörper gegen CGRP oder den CGRP-Rezeptor in der Migräneprophylaxe

2020 ◽  
Vol 39 (07/08) ◽  
pp. 490-494
Author(s):  
Borries Kukowski
Keyword(s):  
Monoklonale Antikörper ◽  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Calcitonin Gene

ZUSAMMENFASSUNGDie Charakterisierung von calcitonin gene-related peptide (CGRP) als Schlüsselmolekül in der Pathophysiologie der Migräne hat nicht nur unser Verständnis der Erkrankung, sondern auch die Entwicklung neuer Therapien vorangetrieben. Seit kurzem steht mit den monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor eine spezifische und hoch selektive Option für die medikamentöse Prophylaxe der episodischen und chronischen Migräne zur Verfügung, die in zahlreichen klinischen Studien ihre Überlegenheit gegenüber Placebo belegt hat. Hier werden Erfahrungen aus dem praktischen Behandlungsalltag zur kurz- und mittelfristigen Wirksamkeit und Verträglichkeit mitgeteilt und weitere Aspekte wie Therapiewechsel bei Non-Response, Verlauf nach Therapieende und die Frage des Wirkungsortes unter Einbeziehung bereits publizierter Daten angesprochen.

Sign in / Sign up

Export Citation Format

Share Document